Pre-made Tanezumab benchmark antibody ( Whole mAb, anti-NGFB/NGF therapeutic antibody, Anti-HSAN5 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tanezumab biosimilar, Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006.
| Products Name (INN Index) | Pre-Made Tanezumab biosimilar, Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody |
|---|---|
| INN Name | Tanezumab |
| Target | NGF |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | 4edw:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | Rinat Neuroscience,Pfizer |
| Conditions Approved | NA |
| Conditions Active | Back pain,Cancer pain,Musculoskeletal pain |
| Conditions Discontinued | Diabetic neuropathies,Postherpetic neuralgia |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | NGFB |
| Package |
